Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Effectiveness of PRG2302 in R/R B-ALL
NCT06659653Phase 1Recruiting
- Start
- May 2024
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRG-2302 in B cell acute lymphoblastic leukemia (B-ALL). Primary endpoints: Safe dose of PRG-2302 infusion at 24 months and Occurrence of AE after PRG-2302 infusion at 24 months. Started May 2024; status: recruiting.
02
Drugs
PRG-2302
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06659653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06659653.